Áreas Temáticas >
Esquizofrenia y otras Psicosis >
Por favor, use este identificador para citar o enlazar este registro:
|Título: ||Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral Olanzapine.|
|Autor: ||Schreiner, A.|
|Fecha: ||jun-2010 |
|Tipo de documento: ||Comunicación congreso|
|Resumen: ||*Among patients transitioned to paliperidone ER for the main reason of lack of efficacy with their previous oral olanzapine, 57% had an improvement in PANSS total scores of 20% from baseline to endpoint.
*Among patients switching to paliperidone ER from oral olanzapine for main reasons of lack of tolerability, lack of compliance, or other reasons, PANSS total score at endpoint was non-inferior to PANSS total score at baseline.
*Even more, PANSS total score from baseline to endpoint improved significantly for patients switching to paliperidone ER from olanzapine for reasons of lack of tolerability and lack of compliance (P < 0.0001).
*Clinically relevant and statistically significant improvements occurred in PANSS total, subscale, and Marder factor scores (P < 0.0001), with significant improvements in PANSS total scores noted at the first
post-baseline assessment (4 weeks after initiating paliperidone ER).
*The percentage of patients with varying degrees of disability or poor function decreased from 84% at baseline to 68% at endpoint.
*Patient satisfaction, an important predictor for adherence to treatment, was good or very good in 21% of patients
previously unsuccessfully treated with olanzapine.
*Patient satisfaction after treatment with paliperidone ER was good or very good in 65% of patients.
*TEAEs occurring in 5% of patients were insomnia (15.2%), anxiety (7.8%), and somnolence (5.1%).
*ESRS scores decreased (i.e. improved) statistically significantly from 2.8 ± 4.9 to 2.0 ± 4.3 (P < 0.0001).
*Mean body weight change from baseline to endpoint was −0.8 ± 5.2 kg. This small change was statistically significant but not clinically relevant.
*These data support results from recent studies2,3 showing that flexibly dosed paliperidone ER in non-acute patients with schizophrenia is safe, well tolerated, and efficacious, including patients
previously unsuccessfully treated with oral
|Descripción: ||Póster presentado en: 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress 2010. Hong Kong: 6-10 Junio de 2010.|
|URL persistente: ||http://hdl.handle.net/10401/1485|
|Aparece en las colecciones: ||Esquizofrenia y otras Psicosis|
Ficheros en este registro:
Los registros de Bibliopsiquis están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.